Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
21/03/2022 06:11
ZURICH, March 21 (Reuters) - Lonza Group LONN.S said on
Monday it signed a manufacturing agreement with Sweden's Oasmia
Pharmaceutical OASM.ST for ovarian cancer drug candidate
Cantrixil that was licensed by Oasmia from the Australian
pharmaceutical company Kazia last year.
Under the agreement, Lonza will provide kilogram-scale
synthesis, purification, and stability testing of Cantrixil, and
deliver cGMP batches of drug substance for clinical supply, the
company said in a statement.
Manufacturing is expected to begin this month at Lonza’s
recently expanded production facility at Nansha in China, the
company said.
(Reporting by Silke Koltrowitz
Editing by Paul Carrel)
((silke.koltrowitz@thomsonreuters.com; +41 41 528 3638;))